The FDA has approved a new drug called ensartinib for adults with a type of lung cancer called ALK-positive non-small-cell lung cancer (NSCLC).
Entrectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for High-Grade Glioma.
College of Stomatology, Hospital of Stomatology/Guangxi Key Laboratory of Nanobody Research/Guangxi Nanobody Engineering Research Center/School of Basic Medical Sciences/Affiliated Tumor Hospital, ...
Chen et al. developed a simple and sensitive fluoroimmunoassay (FIA) based on a nanobody-alkaline phosphatase fusion protein (VHHjd8-ALP) and blue-emissive carbon dots (bCDs) for the rapid detection ...
Blood routine and liver function tests showed no obvious abnormalities, with a serum creatinine level of 119 µmol/L, urine protein level at 2+, and ... levels were 144 pg/mL–157 pg/mL, alkaline ...
The Food and Drug Administration has approved Ensacove for patients with ALK-positive locally advanced or metastatic ...
Ensartinib offers improved progression-free survival for ALK-positive NSCLC compared with crizotinib, with a median PFS of 25.8 months vs 12.7 months. Adverse events with ensartinib are mostly ...
2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19 February 2025: Annual report 202 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback